Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. QGEN
stocks logo

QGEN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
528.80M
+1.46%
0.596
-2.32%
510.39M
+5.57%
0.579
+5.33%
558.30M
+4.64%
0.643
+7.11%
Estimates Revision
The market is revising Downward the revenue expectations for Qiagen N.V. (QGEN) for FY2025, with the revenue forecasts being adjusted by -0.46% over the past three months. During the same period, the stock price has changed by -0.99%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.46%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.54%
In Past 3 Month
Stock Price
Go Down
down Image
-0.99%
In Past 3 Month
Wall Street analysts forecast QGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QGEN is 49.34 USD with a low forecast of 45.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast QGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QGEN is 49.34 USD with a low forecast of 45.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 47.080
sliders
Low
45.00
Averages
49.34
High
55.00
Current: 47.080
sliders
Low
45.00
Averages
49.34
High
55.00
Berenberg
Harry Gillis
Buy
downgrade
2025-11-12
Reason
Berenberg
Harry Gillis
Price Target
2025-11-12
downgrade
Buy
Reason
Berenberg analyst Harry Gillis lowered the firm's price target on Qiagen to EUR 46 from EUR 50 and keeps a Buy rating on the shares.
TD Cowen
Hold
downgrade
$50 -> $48
2025-11-10
Reason
TD Cowen
Price Target
$50 -> $48
2025-11-10
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on Qiagen to $48 from $50 and keeps a Hold rating on the shares. The firm updated its model as its Q3 report reflected solid trends while the Q4 and 2026 outlook were drags.
Baird
Outperform
to
NULL
downgrade
$49 -> $46
2025-11-06
Reason
Baird
Price Target
$49 -> $46
2025-11-06
downgrade
Outperform
to
NULL
Reason
Baird lowered the firm's price target on Qiagen to $46 from $49 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
TD Cowen
Dan Brennan
Hold
maintain
$49 -> $52
2025-08-07
Reason
TD Cowen
Dan Brennan
Price Target
$49 -> $52
2025-08-07
maintain
Hold
Reason
TD Cowen analyst Dan Brennan raised the firm's price target on Qiagen to $52 from $49 and keeps a Hold rating on the shares. Following a modest beat and raise print, the conference call was largely "steady as she goes," with CEO/CFO discussing ongoing traction with the growth of their 5 Pillars enhanced via numerous R&D initiatives, navigating through tariff margin pressures, and a consistent capital allocation strategy, the firm notes.
Berenberg
Sam England
Buy
maintain
2025-07-24
Reason
Berenberg
Sam England
Price Target
2025-07-24
maintain
Buy
Reason
Berenberg analyst Sam England raised the firm's price target on Qiagen to EUR 50 from EUR 48 and keeps a Buy rating on the shares.
Morgan Stanley
Equal Weight
maintain
2025-06-30
Reason
Morgan Stanley
Price Target
2025-06-30
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Qiagen to EUR 43 from EUR 42 and keeps an Equal Weight rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Qiagen NV (QGEN.N) is 19.01, compared to its 5-year average forward P/E of 21.45. For a more detailed relative valuation and DCF analysis to assess Qiagen NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
21.45
Current PE
19.01
Overvalued PE
23.88
Undervalued PE
19.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
14.74
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.26
Undervalued EV/EBITDA
13.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.11
Current PS
0.00
Overvalued PS
5.62
Undervalued PS
4.60
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 286.76% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

QGEN News & Events

Events Timeline

(ET)
2025-11-04
13:10:25
Qiagen increases FY25 adjusted EPS forecast to approximately $2.38, surpassing consensus of $2.37
select
2025-11-04
13:07:58
Qiagen Announces Q3 Adjusted EPS of 61 Cents, Exceeding Consensus Estimate of 59 Cents
select
2025-11-04
13:05:44
Qiagen to purchase Parse Biosciences for a total of up to $280 million
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-26NASDAQ.COM
Recent Clinical Findings Support Hologic's Breast Cancer Innovations

  • AI in Mammography: The global AI in breast imaging market is projected to grow at a CAGR of 3.30% through 2034, driven by rising breast cancer rates and technological advancements, with Hologic presenting new data on its AI technologies at the RSNA 2025 Annual Meeting.

  • Hologic's Innovations: Hologic's 3DQuorum imaging technology has shown potential to streamline radiologists' workflows without compromising cancer detection rates, while its Genius AIDetection solution performed comparably to radiologists in detecting cancers, albeit with lower specificity.

  • New Developments in Healthcare Technology: QIAGEN introduced the QIAsymphony Connect for automated nucleic acid purification, and GE Healthcare launched the Genesis Radiology Workspace to enhance radiology workflows and patient care.

  • Investment Insights: The AI sector is expected to create significant wealth, with a shift from the initial wave of AI stocks to emerging companies poised for growth, as highlighted in Zacks' report on the next phase of the AI boom.

[object Object]
Preview
5.0
11-21Yahoo Finance
Oracle Appoints Stephen Rusckowski to Its Board of Directors

  • New Board Member Announcement: Oracle Corporation has elected Stephen Rusckowski to its Board of Directors, increasing the board size to 14 members, effective November 18, 2025.

  • Rusckowski's Background: Stephen Rusckowski is the former CEO of Quest Diagnostics and has extensive experience in healthcare and technology, having also served as CEO of Philips Healthcare.

  • Board Chairman's Statement: Larry Ellison, Oracle's Board Chairman, emphasized that Rusckowski's experience will provide valuable insights for Oracle Health to better serve patients and healthcare providers.

  • Board Term Details: Members of Oracle's Board serve one-year terms, with the next election scheduled for November 2026 during the company's annual meeting of stockholders.

[object Object]
Preview
5.0
11-13NASDAQ.COM
Hologic Broadens Availability of Genius Digital Diagnostics System in Europe

  • Hologic's Genius Digital Diagnostics System: Hologic's Genius Digital Diagnostics System has received expanded CE marking in the EU, allowing it to image and review both cell and tissue specimens, enhancing efficiency in disease screening and diagnosis.

  • Thermo Fisher Scientific's Innovations: Thermo Fisher Scientific has secured FDA clearance for the EXENT Analyser and Immunoglobulin Isotypes Assay, an automated platform aimed at improving diagnosis for multiple myeloma, and announced plans to acquire Clario Holdings, Inc.

  • QIAGEN's New Platform Launch: QIAGEN introduced the QIAsymphony Connect at the AMP annual meeting, featuring improvements in nucleic acid purification, and has agreed to acquire Parse Biosciences for advancements in single-cell research.

  • Market Performance and Future Outlook: Hologic's shares have increased by 34.8% over the past six months, outperforming the industry, while the demand for data is driving growth in the semiconductor market, with emerging companies poised to benefit.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Qiagen NV (QGEN) stock price today?

The current price of QGEN is 47.08 USD — it has increased 0.56 % in the last trading day.

arrow icon

What is Qiagen NV (QGEN)'s business?

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

arrow icon

What is the price predicton of QGEN Stock?

Wall Street analysts forecast QGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QGEN is 49.34 USD with a low forecast of 45.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Qiagen NV (QGEN)'s revenue for the last quarter?

Qiagen NV revenue for the last quarter amounts to 532.58M USD, increased 6.12 % YoY.

arrow icon

What is Qiagen NV (QGEN)'s earnings per share (EPS) for the last quarter?

Qiagen NV. EPS for the last quarter amounts to 0.60 USD, increased 33.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Qiagen NV (QGEN)'s fundamentals?

The market is revising Downward the revenue expectations for Qiagen N.V. (QGEN) for FY2025, with the revenue forecasts being adjusted by -0.46% over the past three months. During the same period, the stock price has changed by -0.99%.
arrow icon

How many employees does Qiagen NV (QGEN). have?

Qiagen NV (QGEN) has 5765 emplpoyees as of December 05 2025.

arrow icon

What is Qiagen NV (QGEN) market cap?

Today QGEN has the market capitalization of 10.21B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free